ArticleThe American journal of case reports2025
Colorectal Cancer with Ovarian Metastasis After Panitumumab and FOLFOX4: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Colorectal cancer is now one of the most common malignancies worldwide. Systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of multiple drug combinations. Patients with mCRC and left-sided KRAS/NRAS/BRAF wild-type tumors may benefit from epidermal growth factor receptor (EGFR) inhibitors such as cetuximab or panitumumab in combination with chemotherapy. This report describes the case of a 67-year-old woman with advanced wild-type (WT) KRAS sigmoid colon adenocarcinoma in remission following treatment with panitumumab-FOLFOX4, presenting with ovarian metastases. CASE REPORT We present the case of a 67-year-old woman who was diagnosed with sigmoid colon cancer with metastasis to the periaortic lymph nodes. Due to the wild-type tumor subtype, targeted treatment with panitumumab and FOLFOX4 chemotherapy was implemented. Upon the third follow-up evaluating the effectiveness of therapy, complete remission (CR) was confirmed. During a routine follow-up at the gynecologist, a gynecologic ultrasound performed showed a questionable left adnexal mass, suspicious for primary ovarian cancer. Histopathological examination revealed metastatic adenocarcinoma of the colon. Imaging studies confirmed significant cancer progression. The chemotherapy regimen was changed to FOLFIRI. Imaging studies evaluating the effectiveness of therapy were performed every 3 months, confirming disease stabilization. The patient is still alive and continues to receive systemic therapy. CONCLUSIONS This case report supports previous studies, reports, and clinical trial data showing that treatment with panitumumab-FOLFOX4 can lead to a response in patients with advanced colonic adenocarcinoma and shows the importance of patient selection using molecular diagnostics, including KRAS mutation testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.